In the biotech market,
Cencora (COR) is eliciting a range of responses. The company has a
strong presence and offers encouraging reasons for stakeholders to hold its shares. Noticeably, it's gaining the attention of
Legal & General Group Plc, and
British Columbia Investment Management Corp, with both increasing their positions. Cencora had an unpleasant experience with a
data breach earlier this year but bounced back and annouced
Q3 earnings that beat expectations, boosting its stock.
Walgreen Boots Alliance has however sold a substantial amount of its shares in the company. Its stocks fluctuated in the market, having hit a
52-week high after a promising surge of
16.6% YTD and then facing a steep decline.
CEO Steven Collis and Executive Vice President Gina Clark have also sold a considerable amount of their shares suggesting possible internal doubts. Remaining optimisitic, Cencora elects a
new board member, and achieved milestones such as an
80-plus Relative Strength Rating. Finally,
Bank of America has revised its rating for the company to
'Neutral'.
Cencora COR News Analytics from Fri, 03 Nov 2023 07:00:00 GMT to Sun, 29 Sep 2024 18:49:23 GMT -
Rating 0
- Innovation -3
- Information 5
- Rumor -1
